HPV 相关疾病治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032 年

HPV Associated Disorders Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月30日 | 出版商:

Global Market Insights Inc. | 英文 235 Pages | 商品交期: 2-3个工作天内

价格

简介目录

受 HPV 相关癌症盛行率上升以及诊断技术进步的推动，2023 年全球 HPV 相关疾病治疗市场规模为 196 亿美元，2024 年至 2032 年复合年增长率将达到 4.9%。随着人们对 HPV 与各种癌症之间关联的认识不断提高，越来越多的人寻求检测和治疗方案。诊断工具的创新提高了 HPV 检测的准确性和速度，从而可以进行早期干预。人们对 HPV 相关疾病的预防和有效管理的日益关注可能会增加对标靶治疗和筛检计划的需求，进一步推动市场成长。

HPV 相关疾病治疗行业疾病类型、治疗类型、最终用途和区域。

由于导致子宫颈上皮内瘤 (CIN) 的高盛行率，子宫颈上皮内瘤 (CIN) 领域的销售额在 2023 年达到 61 亿美元。随着人们对疾病的认识不断增强，对有效筛检和治疗方案的需求也不断增加。诊断技术的进步可以实现早期检测和干预，从而改善患者的治疗结果。此外，疫苗等标靶治疗和预防措施的出现，进一步增强了对 CIN 管理的关注，巩固了其在市场上的主导地位。

2023 年，药物细分市场的份额达到 68.3%，这主要是由于有效的抗病毒疗法和 HPV 相关疾病的治疗方法越来越多。随着人们对 HPV 对健康影响的认识不断增强，患者正在寻求医疗解决方案来管理和治疗相关疾病。药物配方的创新，包括标靶治疗和免疫疗法，提高了治疗效果。此外，新药物和联合疗法的持续开发将推动市场成长，巩固药物领域的突出地位。

在对 HPV 相关健康问题的高度认识和强大的医疗基础设施的推动下，北美将以 4.5% 的复合年增长率增长，到 2032 年将达到 133 亿美元。该地区受益于先进的诊断技术和广泛的治疗选择，包括疫苗和药物。旨在提高疫苗接种率和早期检测的公共卫生措施进一步支持市场成长。此外，对创新疗法研发的大量投资有助于创造一个繁荣的市场环境，使北美成为 HPV 治疗选择全面扩展的关键贡献者。

产业生态系统分析
产业影响力
- 成长动力
  - HPV 感染盛行率增加
  - 诊断技术的进步
  - 提高意识和教育
- 产业陷阱与挑战
  - 疫苗和治疗费用高昂
  - 副作用和安全问题
成长潜力分析
监管环境
未来市场趋势
管道分析
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按疾病类型，2021 - 2032

主要趋势
子宫颈上皮内瘤（CIN）
子宫颈癌
肛门上皮内瘤 (AIN)
肛门癌
尖圭湿疣
其他疾病类型

第 6 章：市场估计与预测：按治疗类型，2021 - 2032 年

主要趋势
药物
- 疫苗
- 抗病毒药物
- 其他药物
手术
- 冷冻疗法
- 雷射手术
- 其他手术类型

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

主要趋势
医院
门诊手术中心
专科诊所
其他最终用户

第 8 章：市场估计与预测：按地区划分，2021 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

Biocon Ltd.
Bristol-Myers Squibb Company
Cleveland Clinic
Eli Lilly and Company
F. Hoffmann-La Roche AG
GlaxoSmithKline plc
Hologic, Inc.
INOVIO Pharmaceuticals
Johnson and Johnson Services Inc. (Janssen Pharmaceutical)
Mayo Foundation for Medical Education and Research (MFMER).
Memorial Sloan Kettering Cancer Center
Merck and Co., Inc.
Pfizer, Inc.
The Johns Hopkins Hospital
Thermo Fisher Scientific Inc.

简介目录

Product Code: 11162

The Global HPV Associated Disorders Treatment Market, witnessed at USD 19.6 billion in 2023, will demonstrate a 4.9% CAGR between 2024 and 2032, spurred by the rising prevalence of HPV-related cancers, coupled with advancements in diagnostic technologies. As awareness of the link between HPV and various cancers increases, more individuals seek testing and treatment options. Innovations in diagnostic tools enhance the accuracy and speed of HPV detection, allowing for earlier interventions. This growing focus on prevention and effective management of HPV-related disorders is likely to boost the demand for targeted therapies and screening programs, further propelling market growth.

The HPV associated disorders treatment industry disease type, treatment type, end-use, and region.

The cervical intraepithelial neoplasia (CIN) segment achieved USD 6.1 billion in 2023, fueled by the high prevalence of HPV infections leading to CIN. As awareness of the condition grows, there is an increasing demand for effective screening and treatment options. Advances in diagnostic technologies allow for earlier detection and intervention, improving patient outcomes. Additionally, the availability of targeted therapies and preventive measures, such as vaccines, further enhances the focus on managing CIN, solidifying its dominant position in the market.

The medication segment secured 68.3% in 2023, primarily due to the increasing availability of effective antiviral therapies and treatments for HPV-related conditions. As awareness of HPV's impact on health grows, patients are seeking medical solutions to manage and treat associated disorders. Innovations in pharmaceutical formulations, including targeted therapies and immunotherapies, enhance treatment efficacy. Furthermore, the ongoing development of new medications and combination therapies will drive market growth, solidifying the medication segment's prominent position.

North America will grow at 4.5% CAGR to reach USD 13.3 billion by 2032, driven by high awareness of HPV-related health issues and robust healthcare infrastructure. The region benefits from advanced diagnostic technologies and a wide range of treatment options, including vaccines and medications. Public health initiatives aimed at increasing vaccination rates and early detection further support market growth. Also, significant investments in research and development for innovative therapies contribute to a thriving market environment, making North America a key contributor to the overall expansion of HPV treatment options.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of HPV infections
  - 3.2.1.2 Technological advancements in diagnostics
  - 3.2.1.3 Rising awareness and education
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of vaccines and treatments
  - 3.2.2.2 Side effects and safety concerns
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Cervical intraepithelial neoplasia (CIN)
5.3 Cervical cancer
5.4 Anal intraepithelial neoplasia (AIN)
5.5 Anal cancer
5.6 Genital warts
5.7 Other disease types

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Medication
- 6.2.1 Vaccines
- 6.2.2 Anti-viral drugs
- 6.2.3 Other medications
6.3 Surgery
- 6.3.1 Cryotherapy
- 6.3.2 Laser surgery
- 6.3.3 Other surgery types

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Ambulatory surgical centers
7.4 Specialty clinics
7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa